MLHP has alot going on ...
Press Release Source: MILLENIA HOPE BIOPHARMA
State of the Corporation - A Message from the President and Chief Scientific Officer, Dr. Bahige M. Baroudy
Friday December 8, 8:30 am ET
MONTREAL, QC and WILMINGTON, DE, Dec. 8 /PRNewswire-FirstCall/ -
Dear Shareholders,
For Millenia Hope (OTC:BB MLHP, Frankfurt-MLF), 2006 was a year dedicated to strategic planning to meet new challenges, to show tangible bottom line results and to foster a business environment conducive to the creation of great shareholder value. By examining our inventory of products and assessing the elements necessary to increase shareholder value, we made a firm commitment to diversification and the broadening of our product base. This led to our acquisitions, which we believe will help us fulfill our business plan in the short, medium and long term.
I would like to summarize the activities and events which occurred in the company over the past twelve months and which I feel place our company in an enviable position in the marketplace:
In early 2006, Millenia Hope's subsidiary corp. acquired the assets of a biopharma company, which included patents and patents pending, 5 million dollars (original cost) worth of scientific equipment, nine years of scientific research and development expertise and a library of 160,000 highly purified fractions from 2,200 plant species. Currently operating under the name of Millenia Hope Biopharma (MHB), it is among the top Phytomics Technology companies in the world.
Since the initial acquisition, MHB has concluded a breakthrough contract, with one of the world's largest cosmetic companies, an important Phase I contract, with a billion dollar international pharma (Les Medicaments Pierre Fabre), is in negotiations with eight more corporations and is in the final stages of concluding a multi-million dollar, multi-year contract with an international consumer giant. This strategic move placed MLHP on a new and elevated playing field; ownership of a diverse set of highly sought after products and patents, as an example: a major plant cell culture discovery and development - parthenolide-free feverfew, an ongoing revenue stream generated from some of the global leaders in their fields, top notch research facilities and enhanced scientific expertise leading to new discoveries and additional patents and patent applications. This ramified scientific infrastructure provides us with the opportunity to disseminate our unique technology globally, targeting the cosmetics, neutriceutical and pharmaceutical industries. In the near term we perceive that our specialized expertise will make us the company of choice in these three important market sectors, whose combined annual sales are in the hundreds of billions of dollars.
MHB's new research and development facility is located in the center of Montreal's pharmaceutical industry and provides us with better access to the trained pharmaceutical staff and the additional high quality space needed to expand manufacturing.
The building has 34,000 sq ft of space of which 12,000 sq ft is manufacturing clean space, 2,000 sq ft is laboratory and 10,000 sq ft is office space. We would like to thank the people of Loblaw for their support of biotech companies, a rarity in Quebec.
Millenia Hope Biopharma has filed an SB-2 with the SEC, pursuant to becoming a public reporting company. MHB has also contracted with a national securities firm, Union Securities, to act as the lead underwriter for a $10 million convertible debenture, earning the investor 10% per year. It is envisioned that this, private placement, will be followed by a listing on the TSX and/ or European or overseas exchange and an IPO.
Millenia has put in place a program to treat major infectious diseases that impact global health and is currently developing treatments for Malaria and HIV/AIDS, two major diseases that continue to be a global challenge as resistance to existing drugs mounts.
Heenan Blaikie, a prestigious Canadian law firm, led in this undertaking by the Rt. Honourable, former Prime Minister of Canada Jean Chretien, a senior - Heenan partner, has teamed up with Millenia Hope in its crusade against malaria. Via their diligent efforts, Millenia is working on forging joint ventures to build manufacturing facilities and distribution centers, for its anti-malaria drug, MalarexMMH(TM)18, in 2 African countries. As a result of this crusade, Millenia has signed an MOU with Suninvest of Angola as a partner for this facility. These contracts will be signed directly with the governments of those countries and represent a major milestone in Millenia's quest to alleviate the human suffering and devastation caused by malaria in Africa and other regions of the world.
Millenia signed an agreement with the Pasteur Institute of Cote D'Ivoire, who will act in an oversight and regulatory capacity in Cote D'Ivoire. The overall objective is the eventual eradication of infectious diseases, initially focusing on Malaria and HIV.
We have also expanded our horizons to the East (China) by signing, with HolleyPharm Group, a Memorandum of Understanding to collaborate on the development of a series of new plant-based products, for the pharmaceutical and herbal markets, using the resources of the two companies.
Thank you for your ongoing financial support and patience. On behalf of my colleagues, at Millenia Hope, let me wish all of you a Happy Holiday Season!
Safe Harbor Statement:
Certain statements made in this release may contain language describing the plans, goals, strategies, intentions, forecasts and expectations of Millenia Hope that may be referred to as "forward-looking statements." Several important factors could cause actual results to differ materially from those in such forward-looking statements, and Millenia Hope could encounter unanticipated obstacles and delays in developing products, services and markets.
--------------------------------------------------------------------------------
Source: MILLENIA HOPE BIOPHARMA
News 
Market Data 
Discover 
